Long Term Study With B2036-PEG
Phase 3
Completed
- Conditions
- Acromegaly
- Registration Number
- NCT00143416
- Lead Sponsor
- Pfizer
- Brief Summary
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
- Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).
Exclusion Criteria
- Switching to other therapeutic methods for acromegaly
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
- Secondary Outcome Measures
Name Time Method PK/PD evaluation
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇯🇵Sannomaru-cho, Naka-ku, Nagoya-shi, Japan